Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985 Sep;41(3):751-70.

Testing for a trend in tumor prevalence rates: I. Nonlethal tumors

  • PMID: 4074825

Testing for a trend in tumor prevalence rates: I. Nonlethal tumors

G E Dinse. Biometrics. 1985 Sep.

Abstract

In the analysis of animal carcinogenicity studies, the standard survival-adjusted test for a dose-related trend in the prevalence of nonlethal tumors is the Hoel-Walburg test, which stratifies on age at death by grouping survival times into intervals. An alternative analysis assesses trend on the basis of the likelihood score test under a logistic model for the prevalence function, which adjusts for survival by including age at death as a continuous regression variable. Extensive simulations demonstrate that the test based on modeling the prevalence log-odds as a linear function of age is more powerful than the Hoel-Walburg test, regardless of the intervals used by the latter to stratify the data. Without incorporating a continuity correction, the size of each test often exceeds the nominal level, especially when the mortality patterns differ across dose groups. Corrected versions of the tests operate at conservative levels, where the degree of conservatism varies with the distribution of the data. When the mortality patterns for the dose groups are similar, both tests have essentially the same power to detect a trend in tumor prevalence rates. However, when mortality varies with dose, the logistic regression test with a linear age term is more powerful than the Hoel-Walburg test, and this gain in power increases as the dose-specific mortality patterns become more disparate.

PubMed Disclaimer

Similar articles

Cited by